Life (Feb 2024)

The Prognostic Value of Olfactory Dysfunction in Patients with COVID-19: The COVIDORA Study

  • Anne-Laure Hamel,
  • Léo Delbos,
  • Pierre-André Natella,
  • Thomas Radulesco,
  • Mihaela Alexandru,
  • Emmanuel Bartaire,
  • Sophie Bartier,
  • Gonda Benoite,
  • Emilie Bequignon,
  • Laurent Castillo,
  • Florence Canouï-Poitrine,
  • Florent Carsuzaa,
  • Alain Corré,
  • André Coste,
  • Vincent Couloigner,
  • Clémentine Daveau,
  • Paul De Boissieu,
  • Guillaume De Bonnecaze,
  • Ludovic De Gabory,
  • Christian Debry,
  • Simon Deraedt,
  • Xavier Dufour,
  • Wissame El Bakkouri,
  • Laurent Gilain,
  • Stéphane Hans,
  • Charlotte Hautefort,
  • Ruben Hermann,
  • Roger Jankowski,
  • Candice La Croix,
  • Jean-Baptiste Lecanu,
  • Olivier Malard,
  • Justin Michel,
  • Yann Nguyen,
  • Jerome Nevoux,
  • Jean-François Papon,
  • Vincent Patron,
  • Marine Prigent,
  • Virginie Pruliere-Escabasse,
  • Marion Renaud,
  • Cécile Rumeau,
  • Dominique Salmon,
  • Nicolas Saroul,
  • Elie Serrano,
  • Christine Nhung Tran Khai,
  • Stéphane Tringali,
  • Eric Truy,
  • Clair Vandersteen,
  • Benjamin Verillaud,
  • Raphaël Veil,
  • Maxime Fieux

DOI
https://doi.org/10.3390/life14030293
Journal volume & issue
Vol. 14, no. 3
p. 293

Abstract

Read online

Background: Among all studies describing COVID-19 clinical features during the first wave of the pandemic, only a few retrospective studies have assessed the correlation between olfac-tory dysfunction (OD) and the evolution of disease severity. The main aim was to assess whether OD is a predictive factor of COVID-19 severity based on the patient’s medical management (outpa-tient care, standard hospital admission, and ICU admission). Methods: A national, prospective, mul-ticenter cohort study was conducted in 20 public hospitals and a public center for COVID-19 screen-ing. During the first wave of the pandemic, from 6 April to 11 May 2020, all patients tested positive for COVID-19 confirmed by RT-PCR underwent two follow-up ENT consultations within 10 days of symptom onset. The main outcome measures were the evolution of medical management (out-patient care, standard hospital admission, and ICU admission) at diagnosis and along the clinical course of COVID-19 disease. Results: Among 481 patients included, the prevalence of OD was 60.7%, and it affected mostly female patients (74.3%) under 65 years old (92.5%), with fewer comor-bidities than patients with normal olfactory function. Here, 99.3% (290/292) of patients with OD presented with non-severe COVID-19 disease. Patients reporting OD were significantly less hospi-talized than the ones managed as outpatients, in either a standard medical unit or an ICU. Conclu-sions: As regards the clinical course of COVID-19 disease, OD could predict a decreased risk of hospitalization during the first wave of the pandemic.

Keywords